Friday, November 21, 2014 2:33:02 PM
From Seymour:
That's well known
That's what we've always done
It's been reported publicly many times
Nothing new there
Sent from my iPhone
Eugene Seymour MD MPH
Chief Executive Officer
NanoViricides, Inc
eugene@nanoviricides.com
www.nanoviricides.com
310-486-5677
"NNVC" on the New York Stock Exchange
On Nov 21, 2014, at 11:34 AM, XXX> wrote:
You said:
If I remember correctly we did 8, sent them out for animal testing took the best two, expanded them to 8, sent out again and then choose the best one
Not doing that with Ebola in the interests of time. Making many more and sending them ALL out at the same time
Speeds up the process
Thus it takes longer on the front end to make all the candidates but shorter on the back end since all of the testing can be done together
Remember? This was yesterday or the day before.
-----Original Message-----
From: EUGENE SEYMOUR <eugeneseymourmd@mac.com>
To: XXX
Sent: Fri, Nov 21, 2014 8:27 am
Subject: Re: questions
What information?
Eugene Seymour, MD MPH
Chief Executive Officer
NanoViricides, Inc
310-486-5677
A New York Stock Exchange Company
Sent from my iPad
On Nov 21, 2014, at 11:26 AM, XXX wrote:
You consider the information about Ebolacide2 development that you answered yesterday unrelated to specifics of NNVC?
Come on Doc.
-----Original Message-----
From: EUGENE SEYMOUR <eugeneseymourmd@mac.com>
To: XXX
Sent: Fri, Nov 21, 2014 8:13 am
Subject: Re: questions
I've stopped responding to general questions like yours because I feel that many people want to know the answer making a forum such as our annual meeting a more appropriate venue for discussion
I have no problem answering questions that are unrelated to specifics of NNVC.
Sincerely,
Eugene Seymour, MD MPH
Chief Executive Officer
NanoViricides, Inc
310-486-5677
A New York Stock Exchange Company
Sent from my iPad
On Nov 21, 2014, at 10:53 AM, XXX wrote:
Thank you for the reply. But candidly, you have been replying to posters on ihub as recently as the 20th. You gave some pretty specific information about the Ebolacide2 number of treatments sent for testing and then went on about the facility. Why are you now deciding that this is no longer proper?
It honestly seems like you are avoiding answering questions that are fair and legitimate.
I am perplexed and disheartened. I have believed in you and Dr. Diwan for over 5 years.
I don't know what to believe now.
The SwingTrade Portfolio is up 42.1% YTD through 8/8/2014, 83.5% in 2013, and 537.4% since inception.
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=105141243
Recent NNVC News
- Form 8-K - Current report • Edgar (US Regulatory) • 08/09/2024 08:30:39 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 08/09/2024 08:05:25 PM
- NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • InvestorsHub NewsWire • 05/02/2024 02:07:42 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/16/2024 09:53:32 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 02/14/2024 09:55:35 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/19/2024 09:44:48 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 12/04/2023 09:08:49 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 10/13/2023 08:30:41 PM
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 09/28/2023 08:44:54 PM
North Bay Resources Commences Operations at Bishop Gold Mill, Inyo County, California; Engages Sabean Group Management Consulting • NBRI • Sep 25, 2024 9:15 AM
CEO David B. Dorwart Anticipates a Bright Future at Good Gaming Inc. Through His Most Recent Shareholder Update • GMER • Sep 25, 2024 8:30 AM
Cannabix Technologies and Omega Laboratories Inc. Advance Marijuana Breathalyzer Technology - Dr. Bruce Goldberger to Present at Society of Forensic Toxicologists Conference • BLOZF • Sep 24, 2024 8:50 AM
Integrated Ventures, Inc Announces Strategic Partnership For GLP-1 (Semaglutide) Procurement Through MedWell USA, LLC. • INTV • Sep 24, 2024 8:45 AM
Avant Technologies Accelerates Creation of AI-Powered Platform to Revolutionize Patient Care • AVAI • Sep 24, 2024 8:00 AM
VHAI - Vocodia Partners with Leading Political Super PACs to Revolutionize Fundraising Efforts • VHAI • Sep 19, 2024 11:48 AM